Insight into the clinical potential of convalescent plasma in patients with coronavirus disease (COVID-19) is important given the severe clinical courses in unvaccinated and seronegative individuals.
A new study estimates that thousands of lives could have been saved during the first year of the COVID-19 pandemic if convalescent plasma had been used more broadly, particularly in outpatients at ...
In a recent study posted to the medRxiv preprint server, researchers report that convalescent plasma treatment is most effective in treating hospitalized coronavirus disease 2019 (COVID-19) patients ...
The FDA’s withdrawal of its authorization for Evusheld, a monoclonal antibody therapy used to prevent and treat Covid-19, leaves no monoclonals available for this purpose. Another monoclonal, ...
Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing ...
Guidance for industry on the use of convalescent plasma for patients with COVID-19 has been updated to reflect the 23 August Emergency Use Authorization (EUA) for the investigational product. The ...
Researchers from the Johns Hopkins Bloomberg School of Public Health supported the first blood center in the U.S. to be granted full FDA approval to provide convalescent plasma to immunocompromised ...
Convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover, according to a national clinical trial ...
In a study published in the New England Journal of Medicine, clinicians and researchers from the CHU of Liège and the University of Liège show that the administration of plasma taken from convalescent ...
Two ongoing trials may provide additional clarity regarding the use of convalescent plasma in patients with Covid-19. The COVIC-19 trial (Early High-Titre Convalescent Plasma in Clinically Vulnerable ...
A new study led by researchers at Johns Hopkins Bloomberg School of Public Health estimates that thousands of lives could have been saved during the first year of the COVID-19 pandemic if convalescent ...
Convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover, according to a national clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results